AIM ImmunoTech Inc (NYSE American: AIM), the biopharma group, told investors it was 'actively seeking' investigators and sites for clinical testing of Ampligen as a prevention and early-onset treatment for coronavirus (COVID-19).
The company is targeting the United States, Europe, Asia and Argentina for the trials and is in the process of soliciting one or more sites and qualified principal investigators in one or more countries, it said in a statement.
AIM said it intends to seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials as rapidly as possible.
"Since the first news of the outbreak, our focus and efforts have been devoted to developing Ampligen as an intranasal and oral protective prophylaxis and as an intravenous early-onset treatment for this highly pathogenic coronavirus," said AIM CEO Thomas K. Equels.
"As front-line workers fighting the pandemic around the world know - and as their families know - they are putting their lives on the line every day by working with COVID-19 patients. For example, health care workers account for a reported 13% of cases in Spain."
Equels added that in the absence of an effective vaccine, the development of early-stage therapies such as Ampligen may be critical both to the health of front-line workers and to blunt the spread of the pandemic.
AIM said it also continues to await results in the six ongoing clinical trials studying the effects of Ampligen on different types of cancers, where steady progress continues to be made.
AIM has reached several significant COVID-19 milestones in the last two months, including filing provisional patent applications to secure the company's intellectual property before seeking domestic and international research partners.
Japan's National Institute of Infectious Diseases (NIID) agreed to experiment with Ampligen as a potential treatment for COVID-19. The testing and research will be conducted by laboratories at the NIID and the University of Tokyo. AIM will report immediately upon receipt of results.
AIM engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in China.
AIM is in discussions with GP-Pharm in Argentina to advance Ampligen for potential use against COVID-19. Ampligen is an approved drug in Argentina for use against myalgic encephalomyelitis/chronic fatigue syndrome.
AIM is in discussions with myTomorrows and Erasmus MC, Rotterdam - where Ampligen was recently used to treat pancreatic cancer patients - to explore expedited pre-clinical and clinical trials of Ampligen.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers.